Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 2.77 EUR -3.82% Market Closed
Market Cap: 29.8m EUR
Have any thoughts about
Biosynex SA?
Write Note

Biosynex SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biosynex SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Biosynex SA
PAR:ALBIO
Total Liabilities & Equity
€208.8m
CAGR 3-Years
-7%
CAGR 5-Years
39%
CAGR 10-Years
39%
Edap Tms SA
NASDAQ:EDAP
Total Liabilities & Equity
€91.5m
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
13%
Biomerieux SA
PAR:BIM
Total Liabilities & Equity
€5.3B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
9%
Carmat SA
PAR:ALCAR
Total Liabilities & Equity
€54.2m
CAGR 3-Years
-15%
CAGR 5-Years
16%
CAGR 10-Years
17%
Visiomed Group SA
PAR:ALVMG
Total Liabilities & Equity
€36.6m
CAGR 3-Years
84%
CAGR 5-Years
15%
CAGR 10-Years
11%
Amplitude Surgical SA
PAR:AMPLI
Total Liabilities & Equity
€279.3m
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

Biosynex SA
Glance View

Market Cap
28.9m EUR
Industry
Health Care

Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

ALBIO Intrinsic Value
7.73 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

What is Biosynex SA's Total Liabilities & Equity?
Total Liabilities & Equity
208.8m EUR

Based on the financial report for Jun 30, 2024, Biosynex SA's Total Liabilities & Equity amounts to 208.8m EUR.

What is Biosynex SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
39%

Over the last year, the Total Liabilities & Equity growth was -23%. The average annual Total Liabilities & Equity growth rates for Biosynex SA have been -7% over the past three years , 39% over the past five years , and 39% over the past ten years .

Back to Top